Good morning :)
Place Order
Add to Watchlist

Neuland Laboratories Ltd

NEULANDLAB

Neuland Laboratories Ltd

NEULANDLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹18,173 cr, stock is ranked 375
High RiskStock is 4.21x as volatile as Nifty
14,165.2510.68% (-1692.95)
14,165.2510.68% (-1692.95)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹18,173 cr, stock is ranked 375
High RiskStock is 4.21x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹18,173 cr, stock is ranked 375
High RiskStock is 4.21x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
64.9814.170.10%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.926.630.50%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.

Investor Presentation

View older 

Nov 6, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 18.57%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.31% to 0.42%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 78.76%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue511.75580.06531.94670.32766.60953.01953.161,200.951,571.121,565.51
Raw Materialssubtract259.57272.33283.36363.03394.41443.04441.79491.98636.491,114.51
Power & Fuel Costsubtract22.2425.7825.9526.8132.7539.2142.2148.6248.72
Employee Costsubtract65.3892.74102.99110.46123.56149.74182.47201.79257.06
Selling & Administrative Expensessubtract51.8139.4547.3546.1546.4273.9363.2180.8094.84
Operating & Other expensessubtract30.5342.2517.3362.0163.6884.1778.7896.1658.89
Depreciation/Amortizationsubtract15.7419.2322.1025.8631.2839.6849.0452.7859.7063.95
Interest & Other Itemssubtract24.4821.0918.9315.6621.5717.9013.5013.0714.0011.08
Taxes & Other Itemssubtract14.6820.321.873.9036.7224.7118.3452.23101.3696.28
EPS30.4052.2513.4715.0412.6062.8549.74127.45233.88218.00
DPS2.000.000.000.002.005.005.0010.0014.0014.00
Payout ratio0.070.000.000.000.160.080.100.080.060.06

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 11PDF
Feb 2PDF
FY 2022

Annual report

PDF

Investor Presentation

May 10PDF
Feb 1PDF
Oct 29PDF
Aug 3PDF
FY 2023

Annual report

PDF

Investor Presentation

May 11PDF
Feb 13PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 3PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 6PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Neuland Laboratories Ltd60.5714.170.10%
Sun Pharmaceutical Industries Ltd45.796.530.74%
Cipla Ltd31.234.800.82%
Mankind Pharma Ltd57.5711.50—

Price Comparison

Compare NEULANDLAB with any stock or ETF
Compare NEULANDLAB with any stock or ETF
NEULANDLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding32.64%4.04%2.34%26.46%34.51%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep20.19%21.57%22.69%24.44%25.72%26.46%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Neuland Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HSBC Small Cap Fund - Growth - Direct Plan

Growth
1.7108%2.01%0.64%58/111 (+5)
HSBC Multi Cap Fund - Growth - Direct Plan

Growth
0.2880%1.38%0.39%63/105 (+3)
Bandhan Small Cap Fund - Growth - Direct Plan

Growth
0.2198%0.53%-0.05%118/193 (-4)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

NEULANDLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.10%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.95 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 12, 2024

Final
Final | Div/Share: ₹14.00

Dividend/Share

₹14.00

Ex DateEx Date

Jul 12, 2024

Cash Dividend

Ex DateEx DateJul 11, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Jul 11, 2023

Cash Dividend

Ex DateEx DateJul 14, 2022

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Jul 14, 2022

Cash Dividend

Ex DateEx DateJun 29, 2021

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Jun 29, 2021

Cash Dividend

Ex DateEx DateNov 10, 2020

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Nov 10, 2020

News & Opinions
Spotlight
Neuland Laboratories Ltd leads losers in 'A' group

Hindustan Zinc Ltd, Five-Star Business Finance Ltd, Great Eastern Shipping Company Ltd and Triveni Engineering and Industries Ltd are among the other losers in the BSE's 'A' group today, 06 November 2024.Neuland Laboratories Ltd tumbled 13.87% to Rs 13640.05 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9892 shares were traded on the counter so far as against the average daily volumes of 2786 shares in the past one month.Hindustan Zinc Ltd lost 7.95% to Rs 514.95. The stock was the second biggest loser in 'A' group.On the BSE, 3.55 lakh shares were traded on the counter so far as against the average daily volumes of 1.69 lakh shares in the past one month.Five-Star Business Finance Ltd crashed 2.98% to Rs 653.55. The stock was the third biggest loser in 'A' group.On the BSE, 1.07 lakh shares were traded on the counter so far as against the average daily volumes of 1.29 lakh shares in the past one month.Great Eastern Shipping Company Ltd pared 2.77% to Rs 1258.15. The stock was the fourth biggest loser in 'A' group.On the BSE, 26481 shares were traded on the counter so far as against the average daily volumes of 24976 shares in the past one month.Triveni Engineering and Industries Ltd corrected 2.67% to Rs 406.1. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.09 lakh shares were traded on the counter so far as against the average daily volumes of 33243 shares in the past one month.Powered by Capital Market - Live

10 hours agoCapital Market - Live
Earnings
Neuland Laboratories consolidated net profit declines 63.20% in the September 2024 quarter

Net profit of Neuland Laboratories declined 63.20% to Rs 32.84 crore in the quarter ended September 2024 as against Rs 89.25 crore during the previous quarter ended September 2023. Sales declined 25.59% to Rs 310.84 crore in the quarter ended September 2024 as against Rs 417.75 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales310.84417.75 -26 OPM %20.0232.91 - PBDT65.50136.10 -52 PBT49.42121.59 -59 NP32.8489.25 -63 Powered by Capital Market - Live

11 hours agoCapital Market - Live
Corporate
Neuland Laboratories to declare Quarterly Result

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 6 November 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live

This Mukul Agrawal-owned stock crossed Rs 10,000-mark; up 725% in 2 years

3 months agoBusiness Standard

Neuland Laboratories consolidated net profit rises 58.16% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
Neuland Laboratories consolidated net profit rises 58.16% in the June 2024 quarter

Net profit of Neuland Laboratories rose 58.16% to Rs 97.87 crore in the quarter ended June 2024 as against Rs 61.88 crore during the previous quarter ended June 2023. Sales rose 21.11% to Rs 439.60 crore in the quarter ended June 2024 as against Rs 362.99 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales439.60362.99 21 OPM %28.0626.70 - PBDT125.4996.75 30 PBT109.2183.16 31 NP97.8761.88 58 Powered by Capital Market - Live

3 months agoCapital Market - Live

Stock Alert: Coal India, Bank of Baroda, Tata Steel, Sonata Software, Aster DM Healthcare

3 months agoBusiness Standard
Corporate
Neuland Laboratories to hold board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 1 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Goldman Sachs Advises Shareholders To Sell And Buy Their Stakes In These Firms - News18

6 months agoNews18
Goldman Sachs Initiates Buy On Syngene, Neuland Labs & A Sell Rating On Laurus Labs | CNBC TV18
6 months agoCNBC-TV18